Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LMDKB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
A7R-ADC-SN38
|
|||||
| Synonyms |
A7R ADC SN38; A7R ADC SN38
Click to Show/Hide
|
|||||
| Organization |
Riken Corp.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Autoimmune disorder [ICD11:4A41-4A4Z]
Clinical candidate
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4-6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-IL7R mAb A7R
|
Antibody Info | ||||
| Antigen Name |
Interleukin-7 receptor subunit alpha (IL7R)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-PEG12-carbamate-PEG27
|
Linker Info | ||||
| Conjugate Type |
SN-38 was conjugated to A7R via the carbamate bonding in generating A7R-ADC-SN-38.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.